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Global transcriptome analysis 
of rat hypothalamic arcuate 
nucleus demonstrates reversal 
of hypothalamic gliosis following 
surgically and diet induced weight 
loss
pernille Barkholt  1,2*, Kristoffer T. G. Rigbolt1, Mechthilde falkenhahn3, Thomas Hübschle3, 
Uwe Schwahn3, Maria Luisa fernandez-cachon3, Thorsten Schmidt3, Stefan theis3, 
Henrik H. Hansen  1, Anders Hay-Schmidt2, Philip J. pedersen1, Niels Vrang1 & Jacob Jelsing1
The central mechanisms underlying the marked beneficial metabolic effects of bariatric surgery are 
unclear. Here, we characterized global gene expression in the hypothalamic arcuate nucleus (Arc) in 
diet-induced obese (DIO) rats following Roux-en-Y gastric bypass (RYGB). 60 days post-RYGB, the 
Arc was isolated by laser-capture microdissection and global gene expression was assessed by RNA 
sequencing. RYGB lowered body weight and adiposity as compared to sham-operated DIO rats. 
Discrete transcriptome changes were observed in the Arc following RYGB, including differential 
expression of genes associated with inflammation and neuropeptide signaling. RYGB reduced gene 
expression of glial cell markers, including Gfap, Aif1 and Timp1, confirmed by a lower number of GFAP 
immunopositive astrocyte profiles in the Arc. Sham-operated weight-matched rats demonstrated a 
similar glial gene expression signature, suggesting that RYGB and dietary restriction have common 
effects on hypothalamic gliosis. Considering that RYGB surgery also led to increased orexigenic and 
decreased anorexigenic gene expression, this may signify increased hunger-associated signaling at the 
level of the Arc. Hence, induction of counterregulatory molecular mechanisms downstream from the 
Arc may play an important role in RYGB-induced weight loss.
Obesity and related co-morbidities are a major threat to both public health and health budgets across the world 
and the search for efficacious treatment options is becoming increasingly critical. Whereas lifestyle interventions 
and pharmaceutical treatments have had limited success in the treatment of obesity, bariatric surgeries are the 
only treatment options providing weight loss of a magnitude matching patient expectations1,2. Consequently, 
understanding the molecular mechanisms behind bariatric surgery could potentially lead to the development of 
new non-surgical approaches to the treatment of obesity.
The hypothalamus is known as the primary integrator of peripheral and central signals involved in homeo-
static regulation of food intake and body weight3. In particular, the hypothalamic arcuate nucleus (Arc) is known 
to play a key role in sensing peripheral hormonal signals and relaying nutritional states to the brain, mainly 
ascribed to two distinct leptin and insulin responsive neuronal populations in the Arc. Dysregulated activity of 
arcuate neurons co-expressing the orexigenic neuropeptides neuropeptide Y (NPY) and agouti-related peptide 
(AgRP) and neurons co-expressing the anorexigenic peptides cocaine- and amphetamine-regulated transcript 
(CART) and pro-opiomelanocortin (POMC)4–6 is, at least in part, known to be responsible for caloric overcon-
sumption and onset of obesity7,8. Recently, pro-inflammatory signaling mechanisms in the Arc have also been 
implicated in the pathogenesis of obesity9,10.
1Gubra, Hørsholm, Denmark. 2Department of Neuroscience and Pharmacology, University of Copenhagen, 
Copenhagen, Denmark. 3Sanofi-Aventis Deutschland GmbH, Frankfurt Am Main, Germany. *email: pb@gubra.dk
open
2Scientific RepoRtS |         (2019) 9:16161  | https://doi.org/10.1038/s41598-019-52257-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
To date, a major focus in bariatric surgery research has been on the impact on gut-derived hormones, bile 
acids, microbiota and other peripheral adaptations11–13. In contrast, only a few studies have addressed cen-
tral mechanisms involved in post-surgical satiety and weight loss. Accordingly, two independent studies have 
indicated transcriptional upregulation of arcuate orexigenic markers in rat models of biliopancreatic14 and 
duodenal-jejunal bypass14,15. Using quantitative in situ hybridization histochemistry (ISHH), we have recently 
reported similar findings in a rat model of Roux-en-Y gastric bypass (RYGB)16. As orexigenic melanin concen-
trating hormone (MCH) gene expression in the lateral hypothalamus was unaffected by RYGB, this suggested 
that compensatory overeating after RYGB surgery is prevented by recruitment of counterregulatory molecular 
signaling pathways downstream from the Arc16. The present study aimed to gain further insight into the gene reg-
ulations in the Arc following RYGB. To this end, laser-capture microdissection (LCM) and RNA sequencing were 
combined to determine global gene expression in the Arc after RYGB-induced weight loss in the diet-induced 
obese rat.
Materials and Methods
Animals. The Danish Animal Experiments Inspectorate approved all experiments which were conducted 
using internationally accepted principles for the use of laboratory animals under the personal license #2013-15-
2934-00784. Male Sprague-Dawley rats (8 weeks old) were obtained from Taconic (Lille Skensved, Denmark). 
Upon arrival, rats were single-housed and maintained in controlled environmental conditions (12 h light/12 h 
dark cycle; 22 ± 1 °C; 50 ± 10% relative humidity). Rats were fed a two-choice diet consisting of chow (Altromin 
1324, Brogaarden Denmark) and a high-palatable high-fat diet (HPHF diet; Nutella, peanut butter and powdered 
chow), as described previously17. Rats had ad libitum access to water and the two-choice diet regimen for 4 (4w 
DIO, n = 16) or 12 (12w DIO, n = 30) weeks to induce mild or severe obesity, respectively, prior to surgical inter-
vention. For 12w DIO rats, body weight and food intake was monitored daily throughout the study. Body weight 
and food intake in the 4w DIO rats has been reported previously16.
Surgical procedures. Rats were assigned to RYGB (4w DIO, n = 8; 12w DIO, n = 10) or sham surgery (4w 
DIO, n = 8; 12w DIO, n = 10). Sham-operated and weight-matched (WM) rats (n = 10) served as an additional 
control group to RYGB in the 12-week pre-feeding study. Three days prior to surgery, animals were placed on 
a liquid diet (Osmolite 1 Cal, Abbott Nutrition, Chicago, IL; Fresubin Original, Mediq Danmark, Broendby, 
Denmark). On the day of surgery, animals underwent whole-body composition analysis by non-invasive 
EchoMRI scanning (EchoMRI-900 Analyzer, EchoMRI, USA). The RYGB surgical procedure were carried out as 
previously described in detail16. In brief, the abdomen was exposed using a midline laparotomy after induction 
of surgical anesthesia with an isoflurane/O2 mixture. The jejunum was transected 30 cm distal to the ligament of 
Treitz, and a longitudinal anti-mesenteric incision was made 10 cm distal to the transected bowel and connected 
to the afferent limb of the jejunum with a running absorbable suture (Ethicon, Somerville, NJ, USA). The stomach 
was exposed, the fundus was excised and a staple line was placed across the waist of the stomach, creating a gastric 
pouch approximately 10% the size of the normal stomach. The distal remnant was returned to the peritoneal cav-
ity and an incision was made on one side of the gastric pouch considering the vascular architecture. The efferent 
limb of the transected jejunum was connected to the gastric pouch with a running suture. After repositioning the 
gastric pouch into the peritoneal cavity, the abdominal wall was closed. The sham procedure followed the steps of 
the RYGB but gastrointestinal surgery only included a transection of the jejunum 30 cm distal to the ligament of 
Treitz, which was immediately re-sutured. Animals were subcutaneously administered with warm saline (37 °C, 
20 ml/kg), enrofloxacin (0.5 mg/kg) and carprofen (0.5 mg/kg) to prevent post-operative infection, lethargy and 
pain relief. The wire grate was kept in place post-operatively for up to 10 days where only liquid diet was offered in 
this period whereupon the two-choice diet was reintroduced. The food ration for 12w DIO-WM rats was adjusted 
on a daily basis to promote a body weight change equal to that of 12w DIO-RYGB rats. A daily check was made to 
ensure that the previous food ration had been consumed.
Termination and tissue sampling. 60 days post-surgery, animals were euthanized by decapitation 
under CO2/O2 anesthesia. All animals were euthanized in the morning 2–3 hours after lights on. RYGB and 
sham-operated animals were euthanized in a randomized order. Prior to euthanasia, animals underwent an addi-
tional whole-body echo-MRI scan. Following decapitation, brains were quickly removed and snap-frozen on 
crushed dry ice and stored at −80 °C until further processing.
Plasma sampling and hormone assays. Blood samples were collected at termination in EDTA-coated 
tubes containing DDP-IV inhibitor (DPP4-010, Millipore, Denmark) and protease inhibitor cocktail (P2714-
1BTL, Sigma-Aldrich, Denmark). Plasma was separated and stored at −80 °C. Leptin, C-peptide, peptide YY 
(PYY) and ghrelin were determined in a rat multiplex assay (#RMHMAG-84K, Merck Millipore, Darmstadt, 
Germany) on a Luminex Flexmap 3D machine (Luminex, Austin, TX). Total and active GLP-1 was determined 
using single-plex assays (K150JVC/K150JWC, Meso Scale Discovery, Rockville, MD) on a MESO QuickPlex SQ 
120 instrument (Meso Scale Discovery, Rockville, MD).
Laser-capture microdissection and RNA sequencing. The brains were sectioned on a cryostat (CM 
3050, Leica, Germany) into 12 μm thick coronal sections using systematic uniform random sampling (Fig. 1A). 
Serial sections covering the entire rostro-caudal axis of the Arc were collected at every 180 μm (i.e. every 15th 
section) on Pen membrane microscope slides (Life Technologies, Carlsbad, CA) for LCM and on super-frost 
plus slides for immunostaining, respectively. For LCM, sections were allowed to thaw for 5 min at 4 °C and then 
stained for 5 min in a 0.1% cresyl violet acetate (Sigma-Aldrich, St. Louis, MI) solution dissolved in 70% ethanol. 
Sections were then dehydrated in 96% and 100% ethanol at 4 °C and finally allowed to dry in fume hood for 2 min 
at room temperature. Using the ArcturusXT LCM Instrument (AXT2148, Life Technologies, Carlsbad, CA) the 
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Arc was identified and captured by a combination of infrared capturing and UV laser cutting. The Arc tissue was 
captured on CapSure® Macro LCM Caps (Applied Biosystems, Foster City, CA). The Arc was collected on 8–10 
sections representing the entire rostro-caudal axis of the nucleus (Fig. 1B). Lysis of cells and RNA extraction 
was performed using the PicoPure RNA isolation kit (Life Technologies, Carlsbad, CA) as recommended. RNA 
integrity was assessed using the Bioanalyzer 2100 system (Agilent Technologies, Waldbronn, Germany). RIN 
(RNA integrity number) values ranged between 7.3–8.1 (data not shown). RNA amplification and sequencing 
was performed on all Arc samples by Cofactor Genomics (Saint Louis, MO). In brief, RNA sequencing (RNAseq) 
libraries were prepared with the Ovation® RNAseq system (NuGen, Redwood City, CA) and sequenced on the 
HiSeq platform (Illumina, San Diego, CA) (single-end, approximately 20 M 75 bp reads). Reads were aligned 
to the Rnor_5.0 Ensembl Rattus norvegicus genome using STAR v.2.3.0 and feature counts were obtained with 
HTseq v. 0.6.1, both with default parameters18,19. Known orexigenic/anorexigenic genes (AgRP, NPY, CART and 
POMC) were selected a priori for analysis of the orexigenic state in the Arc following RYGB. For network analysis 
a raw p-value < 0.01 was used as threshold and protein-protein interaction annotations were obtained from the 
String database20 and imported to Cytoscape21 for visualization. To identify putative associations of gene expres-
sion patterns, the Cytoscape plug-in BINGO22 was used to extract enriched GO terms for each network.
Immunohistochemical analysis of astrocyte profiles. In all individual rats, an additional series of 
cryo-sections was used for glial fibrillary acidic protein (GFAP) immunohistochemistry. Sections were fixated 
in 10% neutral buffered formalin for 10 min followed by rinsing in water. Endogenous peroxidase activity was 
blocked for 10 min in 1% H2O2 + tris buffered saline (TBS) + 0.3% Triton-X (TX). Blocking of unspecific bind-
ing was obtained with 5% swine serum in TBS + 0.3% TX + 1% BSA for 20 min followed by addition of rabbit 
anti-GFAP antibody (1:300; Z0334; Dako, Denmark) diluted in TBS-T + 1% BSA for 60 min. The reaction was 
amplified for 30 min using MACH 2 rabbit HRP-polymer (RHRP520, BioCare Medical, USA). Sections were 
rinsed in TBS before subjected to 3,3′-diaminobenzidine as chromagen (K3467; Dako, Denmark). The evaluation 
of astrocyte profiles was performed on digitalized slides using the newCAST software (Visiopharm, Hørsholm, 
Denmark). A region of interest was delineated and a counting frame was placed using systematic uniform ran-
dom sampling principles. Astrocyte profiles were counted when located within the counting frame. A total num-
ber of approximately 50 counting frames was evaluated.
Statistics. Graphical presentations, calculations and statistical analyses were carried out using GraphPad 
software (GraphPad Prism version 5, San Diego, California, USA). Statistical analysis of in-vivo data, plasma 
analyses and mRNA levels of a priori selected genes were performed using either one-way analysis of variance 
Figure 1. Laser-capture microdissection of the Arc. (A) Illustration of workflow from sectioning of brains 
collecting series of hypothalamic sections through cresyl violet staining to laser capture microdissection (LCM) 
of the Arc and RNA purification; adapted from Paulsen et al.49. (B) Hypothalamic section before and after LCM 
of the Arc.
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(ANOVA) followed by Tukey’s post-hoc test or student’s unpaired t-test where appropriate. A p value less than 
0.05 was considered statistically significant. Differential gene expression analysis was performed using edgeR with 
raw p-values23. Combined p-values were calculated using Fisher’s combined probability test applied separately to 
genes up-regulated or down-regulated in both cohorts.
Results
RYGB induces significant weight loss and increases plasma GLP-1 and PYY levels. Metabolic 
parameters are indicated in Table 1. We have previously reported significantly reduced terminal body weight and 
whole-body fat mass in 4w DIO-RYGB rats compared to 4w DIO-sham controls16. Correspondingly, 12w DIO-
RYGB rats showed significant reductions in terminal body weight relative to baseline (F(2,27) = 4.52, p < 0.001). 
Also, 12w DIO-RYGB rats exhibited lowered terminal whole-body fat mass as compared to 12w DIO-sham con-
trols (F(2,27) = 5.41, p < 0.05). The magnitude of absolute and relative weight loss as well as whole-body fat mass 
reductions in 12w DIO-RYGB rats were comparable to that of Sham-WM rats. Terminal lean mass was unaffected 
by RYGB in 12w DIO rats and slightly reduced in Sham-WM rats (F(2,27) = 3.67, p < 0.05). Cumulated energy 
intake was similar between RYGB and Sham rats in 12w DIO rats whereas Sham-WM rats were significantly food 
restricted (both chow and HPHF diet) in order to match the weight loss of RYGB rats (F(2,27) = 24.81, p < 0.001). 
Furthermore, 12w DIO-RYGB rats had an increased cumulated chow intake as compared to 12w DIO-sham con-
trols (F(2–27) = 18.54, p < 0.001). Terminal plasma hormone levels in 12w DIO rats were significantly changed by 
RYGB (Table 1). Leptin levels were significantly reduced in 12w DIO-RYGB, but not Sham-WM rats, compared 
to 12w DIO-sham controls (F(2,27) = 6.08, p < 0.01). C-peptide levels were significantly reduced in both 12w 
DIO-RYGB and 12w DIO-WM rats (F(2,27) = 9.72, p < 0.001). Plasma total GLP-1 were significantly increased 
in 12w DIO-RYGB rats, as compared to both 12w DIO-sham and Sham-WM rats (F(2.27) = 16.18, p < 0.001). 
Active GLP-1 levels were significantly increased in 12w DIO-RYGB rats compared to both 12w DIO-sham con-
trols (t = 5.37, df = 17, p < 0.01). While total GLP-1 levels were unchanged in 12w DIO-WM rats, active GLP-1 
concentrations were below assay detection level (0.24 pg/ml) in 12w DIO-WM. Total PYY levels were significantly 
increased in 12w DIO-RYGB rats compared to both 12w DIO-sham and 12w DIO-WM rats (F(2.27) = 57.46, 
p < 0.001). Total PYY levels were unchanged in 12w DIO-WM rats. Plasma ghrelin levels were only increased in 
12w DIO-WM rats (F(2.27) = 4.23, p < 0.05). These metabolic effects are in agreement with the consistent find-
ings in clinical studies on RYGB24–26, supporting the translational value of the present DIO rat model of RYGB.
Global gene expression analysis in the arcuate nucleus. LCM on the Arc was used to determine 
a region-specific transcriptional profile of gene regulatory events following RYGB vs. sham-operated and 
sham-WM controls, respectively (Fig. 1). To increase confidence in the observed differential expression, arcuate 
RNAseq data sets from DIO-RYGB rats (4w DIO-RYGB, 12w DIO-RYGB) and DIO-sham rats (4w DIO-sham, 
12w DIO-sham) were pooled and analyzed specifically for differentially expressed genes (DEGs) regulated in 
the same direction in both 4w and 12w DIO-RYGB rats. Using this procedure, a total of 21 DEGs were identified 
(combined FDR <0.05), including 13 downregulated and 8 upregulated genes, respectively (Table 2). Most sig-
nificantly down-regulated genes were associated with astroglial (Gfap, Aqp4, Fabp7) and immune cell (Serping1, 
Fabp4) function. In addition, RYGB promoted significant downregulation of genes associated with extracellular 
matrix (ECM) remodeling and cell migration (Timp1, Tmbim1, Capn3, Ucma). Significantly upregulated genes 
represented transcription factors (Egr1, Egr2), nuclear receptors (Nr4a1, NR4a3) as well as the orexigenic peptide, 
agouti-related peptide (Agrp). The set of 21 genes were more robustly regulated in 4w DIO-RYGB rats compared 
to 12w DIO-RYGB rats (Table 2).
Network analysis and histological validation. Subsequent network analysis of arcuate DEGs in 4w 
DIO-RYGB rats confirmed several significantly downregulated genes (raw p-value below 0.01) being associated 
with glial function, see Fig. 2A. Most marked reductions in expression levels (RPKM values) were observed for 
glia cell-specific genes, including Gfap and Aqp4 (Fig. 2B). Also, the network analysis indicated lowered Gfap 
expression was linked to reduced expression of the microglial marker Aif1 (also known as Iba1), see Fig. 2A,B. 
In addition, the network analysis confirmed reduced expression of genes functionally linking glial cell and com-
plement function, as represented by significant downregulation of Timp1 (Fig. 2A,B). 12w DIO-RYGB and 12w 
DIO-WM rats showed similar degree of downregulation of Gfap, Aqp4, Aif1 and Timp1 expression relative to 12w 
DIO-sham controls (Fig. 2B). Compared to 12w DIO-sham rats, Egr1 expression was significantly down-regulated 
in 12w DIO-RYGB rats, but not 12w DIO-WM rats (Fig. 2C). To further confirm reduced expression of astroglial 
markers following RYGB, we performed quantitative immunohistochemical analysis of GFAP-positive astrocyte 
profiles in the Arc of 4w DIO rats. Compared to 4w DIO-sham rats, 4w DIO-RYGB rats showed significantly 
lowered numbers of GFAP-positive cell profiles (199 ± 11 vs. 169 ± 8, p < 0.05), see Fig. 2D.
Analysis of a priori selected genes. We have previously reported potential changes in orexigenic sign-
aling in 4w DIO-RYGB rats, as determined by ISHH analysis of arcuate AgRP/NPY and POMC/CART mRNA 
expressing neurons16. Combined LCM-RNAseq analysis of arcuate global gene expression confirmed significant 
upregulation of Agrp expression in 4w DIO-RYGB rats compared to 4w DIO-sham controls (p < 0.01). Similarly, 
Agrp expression was significantly upregulated in 12w DIO-RYGB rats (p < 0.001), but not 12w DIO-WM rats, 
see Fig. 3A. Npy expression was only significantly increased 12w DIO RYGB rats (p < 0.01, Fig. 3B). Both Cart 
and Pomc levels were significantly reduced in 4w DIO-RYGB rats (p < 0.01, p < 0.05). While Cart and Pomc lev-
els were unchanged in 12w DIO-RYGB rats (Fig. 3C,D), 12w DIO-WM rats showed reduced expression of Cart 
(p < 0.05, Fig. 3C). The ratio of orexigenic (Agrp + Npy) vs. anorexigenic (Pomc + Cart) gene expression was cal-
culated to provide an index of overall orexigenic signaling status of the Arc. This procedure revealed significantly 
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increased ratios in both 4w DIO-RYGB (p < 0.001), 12w DIO-RYGB (p < 0.001) and 12w DIO-WM rats (all 
p < 0.001), as compared to corresponding sham controls, see Fig. 3E.
Discussion
Here, we employed LCM in combination with RNAseq for a highly sensitive analysis of gene expression changes 
in the hypothalamic Arc following RYGB surgery in the DIO rat. Global gene sequencing indicated that the most 
marked transcriptional changes in the hypothalamic arcuate nucleus following RYGB were associated to mark-
ers of immune function. Notably, Gfap expression and number of GFAP-positive cell profiles were significantly 
downregulated compared to sham-surgery, suggesting reversal of reactive gliosis after RYGB-induced weight loss. 
Moreover, we extend previous findings based on quantitative ISHH technologies and confirm upregulation of 
arcuate orexigenic gene expression markers after RYGB surgery.
The initial identification of downregulated Gfap and Timp1 expression suggested altered glia cell function 
upon RYGB surgery. Whereas Gfap is a well-known marker of astrocytes27, Timp1 is known to be expressed by 
both neurons and astrocytes in response to insults such as ischemia, demyelination and kainate-induced sei-
zures28–30. It has previously been demonstrated that high fat diet and obesity induce a state of inflammation in the 
hypothalamus, as indicated by an increased expression of proinflammatory marker genes (such as IL-1β, IL-6, 
TNF-α, and Gfap)31,32, supported by reports of increased number and ramifications of microglia33 and increased 
numbers of GFAP positive cells34. To further address potential inflammatory changes after RYGB, we performed 
a series of targeted bioinformatics analyses. A network analysis supported reduced expression of several glia cell 
marker genes, as well as genes related to the complement innate immune system, following RYGB. Astrocytes 
and microglia are dynamic cells that are important in maintaining the microenvironment surrounding neurons 
DIO-Sham DIO-RYGB DIO-WM
4 weeks of HPHF feeding prior to surgery (4w DIO)
Pre-surgical body weight (g) 360 ± 7 409 ± 16 —
Terminal body weight (g) 522 ± 19 442 ± 16** —
Body weight change
relative to day-1 (%) 153 ± 6 110 ± 4*** —
Cumulated chow intake (g) 160 ± 43 448 ± 76** —
Cumulated HPHF diet intake (g) 912 ± 42 768 ± 69* —
Cumulated energy intake (kJ) 23 777 ± 627 23 756 ± 1374 —
Pre-surgical fat mass (g) 35 ± 3 53 ± 6* —
Terminal fat mass (g) 98 ± 10 45 ± 3*** —
Pre-surgical lean mass (g) 289 ± 5 341 ± 16* —
Terminal lean mass (g) 371 ± 7 373 ± 17 —
12 weeks of HPHF feeding prior to surgery (12w DIO)
Pre-surgical body weight (g) 728 ± 22 745 ± 23 762 ± 27
Terminal body weight (g) 725 ± 20 620 ± 15** 636 ± 21*
Body weight change
relative to day-1 (%) 99.7 ± 1.1 83.4 ± 0.9*** 83.5 ± 0.4***
Cumulated chow intake (g) 51 ± 10 267 ± 42*** 163 ± 5*/^
Cumulated HPHF diet intake (g) 826 ± 26 861 ± 66 538 ± 16***/^^^
Cumulated energy intake (kJ) 20 420 ± 586 23 818 ± 1 506 14 856 ± 418***/^^^
Pre-surgical fat mass (g) 220 ± 23 224 ± 20 248 ± 13
Terminal fat mass (g) 222 ± 22 147 ± 18* 160 ± 9*
Pre-surgical lean mass (g) 475 ± 8 493 ± 9 467 ± 13
Terminal lean mass (g) 489 ± 12 475 ± 8 452 ± 11*
Leptin (pg/mL) 4218 ± 413 2716 ± 277** 3209 ± 204
C-peptide (pg/mL) 1269 ± 118 807 ± 51** 846 ± 61*
GLP-1 total (pg/mL) 8.2 ± 1.1 44.9 ± 7.8*** 7.9 ± 4.4^^^
GLP-1 active (pg/mL) 0.61 ± 0.7 3.28 ± 0.5** Below LOD
PYY (pg/mL) 21 ± 2 138 ± 16*** 18 ± 1^^^
Ghrelin (pg/mL) 146 ± 27 145 ± 28 234 ± 15*/^
Table 1. In vivo endpoints and plasma hormone levels. Roux-en-Y gastric bypass (RYGB) and weight-matching 
(WM) led to a significant reduction in plasma leptin levels compared to sham-operated controls. RYGB led to an 
increase in the plasma levels of gut-derived hormones GLP-1 (total and active) and PYY relative to both sham 
and Sham-WM, whereas only Sham-WM showed significantly increased plasma levels of ghrelin. LOD, level 
of detection (active GLP-1 was below detection level in sham-WM animals (0.24 pg/mL)). Cumulated energy 
intake includes chow and high palatable high fat (HPHF) diet consumption over the course of the experiments. 
Data on body weight and body composition in the 4w DIO rat study have previously been reported16. Data are 
presented as mean ± SEM; *p < 0.05 vs sham, **p < 0.01 vs sham, ***p < 0.001 vs sham; ^p < 0.05 vs RYGB, 
^^^p < 0.001 vs RYGB (Student’s unpaired t-test or one-way ANOVA with Tukey post-hoc test).
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and in co-modulating neuronal functions, such as synaptic plasticity and metabolism35,36. In response to CNS 
insults, both cell types respond rapidly and develop a reactive phenotype termed reactive gliosis characterized by 
upregulation of specific structural proteins like GFAP in astrocytes37 and allograft inflammatory factor 1 (AIF-
1) in microglia38. The reduction in both Gfap, Aqp4 and Aif1 expression after RYGB therefore suggests ongoing 
processes towards reversal of gliosis. Since data from WM controls demonstrated similar alterations, the revers-
ing of gliosis appears to be an effect of weight loss per se, rather than specific to RYGB surgery. In line with this, 
Grayson and coworkers39 have reported reduced microglia infiltration in the hippocampus following RYGB, and 
pair-feeding leads to a similar improvement. RYGB also resulted in increased expression of the transcription 
factors Egr1 and Egr2. Interestingly, this effect was not observed in WM animals. Although the implications of 
regulated Egr1/Egr2 expression in the Arc is not fully understood, Egr1 expression has been associated with appe-
tite signaling. For example, central infusion of NPY increases Egr1 protein levels in the Arc, and downregulation 
of Egr1 results in halted post-translational processing of POMC into α-MSH40. As systemic administration of 
Ensembl ID Gene Function
4w DIO-RYGB 12w DIO-RYGB Combined
RPKM Ratio
Raw
p-value FDR RPKM Ratio
Raw
p-value FDR
Raw
p-value FDR
Downregulated
ENSRNOG00000002919 Gfap Astroglial cell morphology 429 0.38 1.37E-09 1.02E-05 428 0.73 5.08E-06 5.46E-02 2.34E-13 1.52E-09
ENSRNOG00000010208 Timp1
Extracellular matrix 
remodeling, cell 
migration
47 0.44 2.25E-07 1.11E-03 22 0.82 4.99E-03 8.00E-01 2.43E-08 6.71E-05
ENSRNOG00000010805 Fabp4 Fatty acid trafficking, inflammation 2.0 0.07 8.19E-11 1.22E-06 0.2 0.49 1.19E-01 9.95E-01 3.06E-07 1.94E-03
ENSRNOG00000016043 Aqp4 Astrocyte water homeostasis 300 0.67 2.57E-04 1.69E-01 905 0.85 7.91E-04 3.92E-01 3.33E-06 3.62E-03
ENSRNOG00000000814 Fabp7 Fatty acid trafficking, glial cell proliferation 296 0.56 3.36E-05 4.54E-02 81 0.88 8.89E-03 8.00E-01 4.80E-06 4.47E-03
ENSRNOG00000013654 Cbln2 Synapse assembly 28 0.66 2.58E-03 4.79E-01 33 0.80 1.59E-04 2.67E-01 6.44E-06 5.25E-03
ENSRNOG00000007457 Serping1 Regulation of complement cascade 13 0.57 3.73E-03 5.33E-01 15 0.78 1.87E-04 2.67E-01 1.06E-05 6.92E-03
ENSRNOG00000058906 Ptprh Regulation of cell growth 0.6 0.25 2.50E-06 6.19E-03 2.0 0.92 5.54E-01 9.95E-01 2.01E-05 1.19E-02
ENSRNOG00000023546 Hspb1 Regulation of cell growth 8.3 0.46 5.81E-05 5.51E-02 4.8 0.82 2.75E-02 8.98E-01 2.29E-05 1.25E-02
ENSRNOG00000006735 Cdkn2b Regulation of cell growth 1.3 0.38 1.99E-06 5.51E-02 3.4 0.84 1.88E-01 9.95E-01 5.90E-06 1.55E-02
ENSRNOG00000014797 Tmbim1
Extracellular matrix 
remodeling, cell 
migration
29 0.66 2.15E-05 3.78E-02 26 0.94 1.28E-01 9.63E-01 3.81E-05 1.78E-02
ENSRNOG00000008609 Capn3
Extracellular matrix 
remodeling, cell 
migration
3.0 0.49 1.29E-04 1.01E-01 6.7 0.85 3.17E-02 9.00E-01 5.50E-05 2.39E-02
ENSRNOG00000017987 Ucma
Extracellular matrix 
remodeling, cell 
migration
12 0.41 9.79E-06 5.51E-02 2.4 0.75 1.51E-01 9.95E-01 2.14E-05 3.74E-02
Upregulated
ENSRNOG00000019422 Egr1 Transcription factor 17 4.28 4.45E-07 1.65E-03 35 1.48 3.25E-03 6.70E-01 3.09E-08 6.71E-05
ENSRNOG00000039001 Agrp Appetite stimulation 185 1.53 5.68E-03 6.68E-01 55 1.93 1.84E-05 8.83E-02 1.78E-06 2.90E-03
ENSRNOG00000000640 Egr2 Transcription factor 0.7 3.17 2.29E-05 3.78E-02 3.1 1.59 8.26E-03 8.00E-01 3.11E-06 3.62E-03
ENSRNOG00000002793 Sstr2
Hormone secretion, 
regulation of cell 
growth
6.0 1.79 1.98E-06 5.89E-03 14 1.06 3.39E-01 9.95E-01 9.99E-06 6.92E-03
ENSRNOG00000007830 Apold1 Endothelial cell signaling 1.7 2.83 1.96E-05 3.78E-02 4.8 1.19 1.17E-01 9.59E-01 3.22E-05 1.62E-02
ENSRNOG00000005964 Nr4a3 Nuclear receptor 2.8 2.14 2.87E-05 4.27E-02 16.6 1.09 1.62E-01 9.70E-01 6.16E-05 2.51E-02
ENSRNOG00000007637 Acer2 Ceramide metabolism 4.8 1.45 2.16E-02 9.01E-01 27.5 1.28 3.51E-04 2.67E-01 9.72E-05 3.52E-02
ENSRNOG00000007607 Nr4a1 Nuclear receptor 2.7 3.07 2.67E-04 1.69E-01 5.4 1.33 4.09E-02 9.00E-01 1.36E-04 4.66E-02
Table 2. Differentially expressed genes in the n. arcuatus of RYGB-operated DIO rats. Arcuate transcriptome 
analysis was performed 60 days following RYGB. Data are shown for individual experiments as well as following 
combined analysis. Combined statistical analysis of RNAseq data from both 4w DIO and 12w DIO rats 
indicated differential gene expression (FDR <0.05) of 21 genes (downregulated, n = 13; upregulated, n = 8) 
following RYGB, as compared to sham-operated controls. Genes are ranked according to combined FDR value. 
Gene expression level of individual genes is indicated by RPKM value. Ratio indicates gene expression level 
following RYGB surgery relative to corresponding sham group (RYGB/sham).
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Figure 2. Reduced expression of inflammatory marker genes after RYGB. (A) Network analysis of all genes 
with raw p-values below 0.01 demonstrated several genes specific for glia cells as well as the complement 
immune system to be downregulated in RYGB-operated DIO (DIO-RYGB) rats relative to sham-operated DIO 
(DIO-sham) rats. (B) Expression levels of glia cell marker genes were downregulated following RYGB surgery 
in both studies (scale bar, 20 µm). (C) The transcription factor Egr1 was upregulated in both 4w and 12w DIO-
RYGB rats. (D) Expression levels are presented as mean reads per kilobase million (RPKM) ±SEM; statistical 
analysis was performed using EdgeR presented with raw p-values; *p < 0.05, **p < 0.01, ***p < 0.001. (D) 
The number of GFAP-positive astroglia profiles was significantly downregulated in 4w DIO-RYGB relative to 
4w DIO-sham controls. Representative micrographs of GFAP-immunostained sections from sham-operated 
and RYGB-operated animals with arrowheads identifying astrocytes; scalebar equal to 20 µm in inserts. GFAP-
positive cell counts are presented as mean ± SEM; *p < 0.05 (Student’s unpaired t-test). Gene names: Aif1, 
Allograft inflammatory factor 1; Anxa2, Annexin A2; Anxa5, Annexin A5; Arpc1b, Actin-related protein 2/3 
complex subunit 1B; Aqp4, Aquaporin 4; C1s, Complement component 1s; C1qb, Complement component 1q B 
chain; Egr1, Early growth response protein 1 (also known as Zif268); Gfap, Glial fibrillary acidic protein; S100B, 
S100 calcium-binding protein B; Lgals1, Galectin-1 (lectin, galactose binding, soluble 1); Serping1, Serpin 
peptidase inhibitor, clade G (C1 inhibitor) member 1; Timp1, Tissue inhibitor of metalloprotease 1.
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ghrelin also upregulates arcuate Egr1 protein expression in both fasted and fed rats41, this suggests a complex role 
of Egr1 in both orexigenic and anorexigenic signaling.
Using quantitative ISHH, we have previously reported that RYGB increases NPY and AgRP mRNA expres-
sion in the Arc without affecting POMC and CART mRNA levels in 4w DIO-RYGB rats, suggesting increased 
orexigenic tone at the level of the mediobasal hypothalamus16. Using combined LCM-RNAseq, we confirmed 
upregulation of arcuate orexigenic signaling in both 4w and 12w DIO-RYGB rats. In addition, LCM-RNAseq 
analysis indicated reduced Pomc and Cart expression in 4w DIO-RYGB rats, but not 12w DIO-RYGB rats. The 
discrepancies may be related to differences in sensitivity using RNAseq compared to ISHH as well as differences 
in pre-surgical body weight. Nonetheless, taken together our data suggest enhanced arcuate orexigenic signaling 
in a DIO rat model of RYGB, and extend findings reported in other rat models of bariatric surgery, including 
biliopancreatic diversion14, vertical sleeve gastrectomy42 and gastric banding43. NPY/AgRP and POMC/CART 
expressing neurons are well-known metabolic sensors highly responsive to changes in feeding status and circulat-
ing levels of nutrients and hormones, including glucose, leptin and insulin (for review see44). As RYGB reduced 
plasma leptin and insulin levels, it may be speculated that improved metabolic status played a role in the adaptive 
changes in the Arc. RYGB also markedly increased plasma levels of GLP-1 and PYY levels, which are gut-derived 
Figure 3. Differential expression of arcuate neuropeptide genes related to hunger and satiety signaling. 
Orexigenic AgRP (A) and NPY (B) mRNAs were elevated after RYGB in both studies relative to sham controls. 
Anorexigenic CART (C) and POMC (D) mRNAs were reduced in RYGB following 4 weeks, but not 12 weeks 
of pre-feeding. Statistical analysis was performed using EdgeR with raw p-values; *p < 0.05, **p < 0.01, 
***p < 0.001 compared to corresponding sham control group. (E) The increased ratio between the expression 
level of orexigenic and anorexigenic genes suggests an orexigenic signaling state following RYGB compared to 
sham surgery; ***p < 0.01 compared with sham (student’s unpaired t-test or one-way ANOVA with Tukey post-
hoc test). Data is presented as mean ± SEM.
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anorectic hormones45,46. We have previously reported RYGB-induced hypertrophy of the rat gut mucosa in the 
food exposed regions of the small intestine, coupled with a doubling in the total number of L-cells and marked 
increases in intestinal preproglucagon and PYY mRNA expression47. Hence, the intestinotrophic effect of RYGB 
likely explains the markedly elevated plasma levels of GLP-1 and PYY in the DIO-RYGB rat. Because WM did not 
increase circulating levels of GLP-1 and PYY, this supports the notion that these hormones are not responsible for 
RYGB-induced weight loss, at least at the level of the Arc48.
conclusion
For the first time, we here present global gene expression analysis of the Arc in a rat model of RYGB surgery. 
By use of highly sensitive cutting-edge technologies (the combination of LCM and RNAseq), we demonstrate a 
marked modulation of immune signaling pathways following RYGB. In particular, mRNAs related to astrocyte 
and microglia function were reduced, suggesting lowered glia cell activity. These findings support that weight loss, 
whether induced by bariatric surgery or caloric restriction, may lead to improved regulation of immune function 
within the Arc.
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